tedizolid and Diabetic-Foot

Dalbavancin is a new antibiotic against multi-drug resistant Gram (+) bacteria. Dalbavancin has an extremely long half-life. Current indication is skin and soft tissue infections (ABSSSI), but researchers have successfully administered it off-label to osteomyelitis (OM) patients.. We present a case of successful treatment of diabetic foot (DF) OM.. A 53-year-old male presented to our DF clinic, with recently diagnosed diabetes mellitus, with very bad glycaemic control (HbA1c=12,5%). He had diabetic neuropathy, but no peripheral arteriopathy. Two months before, because of an accident with hot water, he presented left foot ulcer, followed by ABSSSI and 1. Dalbavancin, due to its extremely long half-life, could potentially be the drug of choice for OM caused by multi-drug resistant Gram (+) cocci, in order to avoid hospitalization, especially on non-complient patients. Further research is necessary.

Topics: Anti-Bacterial Agents; Burns; Daptomycin; Diabetes Mellitus, Type 2; Diabetic Foot; Drug Resistance, Multiple, Bacterial; Enterococcus faecium; Gram-Positive Bacterial Infections; Humans; Linezolid; Male; Middle Aged; Osteomyelitis; Oxazolidinones; Teicoplanin; Tetrazoles; Tigecycline